<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367051</url>
  </required_header>
  <id_info>
    <org_study_id>AMC_2020_0613</org_study_id>
    <nct_id>NCT04367051</nct_id>
  </id_info>
  <brief_title>Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction</brief_title>
  <official_title>Withdrawal of Spironolactone Treatment for Heart Failure With Improved Left Ventricular Ejection Fractraction: an Open-label Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized controlled pilot trial to evaluate whether withdrawal of&#xD;
      spironolactone is safe and associated with re-deterioration of left ventricular function in&#xD;
      patients with heart failure with improved ejection fraction. The aim of current trial is to&#xD;
      test the hypothesis that withdrawal of spironolactone would not be associated with relapse of&#xD;
      significant clinical deterioration of left ventricular systolic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of left ventricular ejection fraction</measure>
    <time_frame>6 month</time_frame>
    <description>Proportion of patients with change of left ventricular ejection fraction declining more than 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical change of left ventricular ejection fraction</measure>
    <time_frame>6 month</time_frame>
    <description>Comparison as continuous variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum level on B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide</measure>
    <time_frame>6 months</time_frame>
    <description>Each serum level transformed with a log value and comparing with baseline level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum level of biomarkers (e.g. soluble ST-2, galectin-3)</measure>
    <time_frame>6 months</time_frame>
    <description>Serum biomarkers such as soluble ST-2, galectin-3 are checked and compared with baseline value for prediction of decreased left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of death, re-hospitalization or visit on emergency department for heart failure</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse clinical events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Withdrawal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spironolactone will be continued during the study period with other medical therapy in combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Withdrawal of Spironolactone</intervention_name>
    <description>Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.</description>
    <arm_group_label>Withdrawal group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuation of spironolactone</intervention_name>
    <description>Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.</description>
    <arm_group_label>Continuation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and capable of providing informed consent and agrees to follow the study&#xD;
             protocol and schedule of clinical follow-up&#xD;
&#xD;
          -  Age between 19 and 80 years old&#xD;
&#xD;
          -  Prior diagnosis of heart failure with reduced left ventricular ejection fraction (LV&#xD;
             EF ≤ 35%) and on medical therapy including spironolactone combined with&#xD;
             angiotensin-converting enzyme or angiotensin receptor blocker or antiotensin receptior&#xD;
             neprilysin blocker, beta-blocker.&#xD;
&#xD;
          -  LV EF ≥ 50% documented with echocardiography performed within a month&#xD;
&#xD;
          -  Documented result of BNP or NT-proBNP level within a month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dyspnea ≥ New York Heart Association (NYHA) functional class III&#xD;
&#xD;
          -  Patients who need to discontinue spironolactone owing to prior adverse event&#xD;
&#xD;
          -  Primary valvular heart disease with at least moderate degree&#xD;
&#xD;
          -  Estimated glomerular filtration rate less than 30 mL/min per 1.73 m2&#xD;
&#xD;
          -  Uncontrolled hypertension defined as blood pressure more than 140/90 mmHg&#xD;
&#xD;
          -  Presence of other clinical reason to continue spironolactone such as myocardial&#xD;
             infarction, primary aldosteronism, and liver cirrhosis&#xD;
&#xD;
          -  Hyperkalemia defined as serum potassium level less than 3.5 mmol per liter&#xD;
&#xD;
          -  Pregnant and/or lactating women&#xD;
&#xD;
          -  Life expectancy less than a year&#xD;
&#xD;
          -  Patients who are not suitable to enrollment by investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sang Eun Lee</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

